Phibro Animal Health director Joyce Lee to resign
Phibro Animal Health Corporation reported that board member Joyce J. Lee, a Class II Director, informed the company on April 13, 2026 that she intends to resign from the Board effective April 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Phibro Animal Health Corporation reported that board member Joyce J. Lee, a Class II Director, informed the company on April 13, 2026 that she intends to resign from the Board effective April 15, 2026. The company stated that Ms. Lee’s resignation is not due to any disagreement regarding its operations, policies, or practices.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation effective date: April 15, 2026
Notice date: April 13, 2026
2 metrics
Resignation effective date
April 15, 2026
Effective date of Joyce J. Lee’s resignation as director
Notice date
April 13, 2026
Date Ms. Lee informed the company of her intent to resign
Key Terms
Class II Director, Emerging growth company, Section 12(b)
3 terms
Class II Director financial
"Ms. Lee was a Class II Director of the Company."
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) regulatory
"Securities registered pursuant to Section 12(b) of the Act"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why did Joyce J. Lee resign from Phibro Animal Health (PAHC)'s board?
Joyce J. Lee informed Phibro Animal Health she will resign as a director effective April 15, 2026. The company stated her resignation was not due to any disagreement over operations, policies, or practices, indicating an orderly and non-contentious board transition.
When does Joyce J. Lee's resignation from Phibro Animal Health (PAHC) take effect?
Joyce J. Lee’s resignation from Phibro Animal Health’s Board of Directors is effective April 15, 2026. She notified the company of her intention to resign on April 13, 2026, allowing a brief transition period before her departure becomes effective.
What role did Joyce J. Lee hold on Phibro Animal Health (PAHC)'s board?
Joyce J. Lee served as a Class II Director on Phibro Animal Health Corporation’s Board. Class designations typically relate to staggered board terms, so her departure affects that specific director class within the company’s overall board structure and governance framework.
Did Phibro Animal Health (PAHC) report any disagreement linked to Joyce J. Lee's resignation?
Phibro Animal Health stated that Joyce J. Lee’s resignation was not the result of any disagreement with the company. This covers its operations, policies, or practices, suggesting her departure reflects personal or other reasons rather than a dispute over corporate matters.
What SEC filing did Phibro Animal Health (PAHC) use to disclose the director resignation?
Phibro Animal Health disclosed Joyce J. Lee’s resignation in a Form 8-K current report. The filing was signed on behalf of the company by Judith Weinstein, Senior Vice President, General Counsel and Corporate Secretary, in accordance with Exchange Act reporting requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates